Leptin: A pivotal mediator of intestinal inflammation in mice

被引:226
作者
Siegmund, B
Lehr, HA
Fantuzzi, G
机构
[1] Univ Colorado, Hlth Sci Ctr, Div Infect Dis, Dept Med, Denver, CO 80262 USA
[2] Univ Mainz, Inst Pathol, D-6500 Mainz, Germany
关键词
D O I
10.1053/gast.2002.33631
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims: In addition to acting as a regulator of food intake and energy expenditure, leptin can also modulate immune and inflammatory responses. The role of leptin in intestinal inflammation is the focus of the present study. Methods: Acute and chronic colitis were induced in leptin-deficient ob/ob or wild-type (WT) mice using dextran sulfate sodium (DSS) or trinitrobenzene sulfonic acid (TNBS). The severity of colitis was evaluated, and possible mechanisms were studied. Results: Leptin directly stimulates intraepithelial lymphocytes (IELs) and lamina propria mononuclear cells (LPMCs). In the DSS acute model, ob/ob mice exhibited a 72% reduction of colitis severity and spontaneous release of proinflammatory cytokines from the colon compared with WT mice. Replacement of leptin in ob/ob mice converted disease resistance to susceptibility, indicating that leptin deficiency, not obesity, accounts for the resistance to acute DSS-induced colitis. During chronic DSS-induced colitis and TNBS-induced colitis, in addition to reduced disease severity, ob/ob mice exhibited a significant attenuation in intestinal inflammation, accompanied by reduced production of cytokines and chemokines. When compared with WT mice, CD8(+) IELs of ob/ob mice were reduced in number as well as in their ability to synthesize interferon gamma. In addition, LPMCs of ob/ob mice showed increased apoptosis in untreated as well as DSS- or TNBS-treated mice. Phosphorylation of signal transducer and activator of transcription 3 and induction of cyclooxygenase 2 were absent in the colon of DSS-fed ob/ob mice. Conclusions: These results show that leptin represents a functional link between the endocrine and immune systems.
引用
收藏
页码:2011 / 2025
页数:15
相关论文
共 67 条
[51]  
Pizarro TT, 1999, J IMMUNOL, V162, P6829
[52]  
Plevy SE, 1997, J IMMUNOL, V159, P6276
[53]   Antitumor necrosis factor therapy for inflammatory bowel disease: A review of agents, pharmacology, clinical results, and safety [J].
Sandborn, WJ ;
Hanauer, SB .
INFLAMMATORY BOWEL DISEASES, 1999, 5 (02) :119-133
[54]   Activation of natural killer T cells by α-galactosylceramide in the presence of CD1d provides protection against colitis in mice [J].
Saubermann, LJ ;
Beck, P ;
De Jong, YP ;
Pitman, RS ;
Ryan, MS ;
Kim, HS ;
Exley, M ;
Snapper, S ;
Balk, SP ;
Hagen, SJ ;
Kanauchi, O ;
Motoki, K ;
Sakai, T ;
Terhorst, C ;
Koezuka, Y ;
Podolsky, DK ;
Blumberg, RS .
GASTROENTEROLOGY, 2000, 119 (01) :119-+
[55]  
Siegmund B, 2001, J PHARMACOL EXP THER, V296, P99
[56]   Neutralization of interleukin-18 reduces severity in murine colitis and intestinal IFN-γ and TNF-α production [J].
Siegmund, B ;
Fantuzzi, G ;
Rieder, F ;
Gamboni-Robertson, F ;
Lehr, HA ;
Hartmann, G ;
Dinarello, CA ;
Endres, S ;
Eigler, A .
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, 2001, 281 (04) :R1264-R1273
[57]   Treatment of murine colitis by Lactococcus lactis secreting interleukin-10 [J].
Steidler, L ;
Hans, W ;
Schotte, L ;
Neirynck, S ;
Obermeier, F ;
Falk, W ;
Fiers, W ;
Remaut, E .
SCIENCE, 2000, 289 (5483) :1352-1355
[58]   CIS3/SOCS3/SSI3 plays a negative regulatory role in STAT3 activation and intestinal inflammation [J].
Suzuki, A ;
Hanada, T ;
Mitsuyama, K ;
Yoshida, T ;
Kamizono, S ;
Hoshino, T ;
Kubo, M ;
Yamashita, A ;
Okabe, M ;
Takeda, K ;
Akira, S ;
Matsumoto, S ;
Toyonaga, A ;
Sata, M ;
Yoshimura, A .
JOURNAL OF EXPERIMENTAL MEDICINE, 2001, 193 (04) :471-481
[59]  
Takeda K, 1998, J IMMUNOL, V161, P4652
[60]   ACTIVATED IMMUNOCOMPETENT CELLS IN RAT COLITIS MUCOSA INDUCED BY DEXTRAN SULFATE SODIUM AND NOT COMPLETE BUT PARTIAL SUPPRESSION OF COLITIS BY FK506 [J].
TAKIZAWA, H ;
SHINTANI, N ;
NATSUI, M ;
SASAKAWA, T ;
NAKAKUBO, H ;
NAKAJIMA, T ;
ASAKURA, H .
DIGESTION, 1995, 56 (03) :259-264